Skip to content

WARRIORS

Women's Aneurysm Research: Repair Immediately or Routine Surveillance, Trial and Registry - WARRIORS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58445
Enrollment
100
Registered
2025-04-25
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal aortic aneurysm Swelling of the main artery in the abdomen

Interventions

Endovascular Aneurysm Repair (EVAR)&nbsp

Sponsors

Imperial College London
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Female sex; age =50 years; Infra-renal abdominal aortic aneurysm with a maximum infrarenal aortic anterior- posterior diameter 4.0-5.4 cm; Local assessment that arterial morphology is suitable for EVAR; Rockwood frailty score <7.

Exclusion criteria

Exclusion criteria: Male sex; Aneurysm of the infrarenal aorta of <4.0 or >5.4cm; Infrarenal aneurysm not meeting Instructions For Use (IFU) for any specific licensed endograft for standard EVAR; Inability to give informed consent; Previous abdominal aortic surgery; Age <50 years; Concomitant thoracic aortic aneurysm of >4.0cm diameter; Excessive frailty (Rockwood score =7); Life expectancy <2 years in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
Composite of AAA rupture and aneurysm-related mortality at 5 years. 

Secondary

MeasureTime frame
Secondary endpoint:  QALYs at 5 years (from quality of life and all-cause mortality).Other endpoints: Operative mortality Anxiety  Costs  Cost-effectiveness •Loss of eligibility for EVAR at the 5.5 cm diameter threshold Major adverse cardiovascular events (MACE), comprising myocardial infarction, stroke and lower limb amputation

Countries

Australia, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, New Zealand, Portugal, Serbia, Sweden, United Kingdom, United States

Contacts

Public ContactJ.L. De Bruin

Erasmus MC, Universitair Medisch Centrum Rotterdam

j.debruin@erasmusmc.nl+31 (0) 107033588

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 20, 2026